E D Razis1, G Fountzilas. 1. 1st Department of Medical Oncology, Hygeia Hospital, Athens, Greece. edrazis@hol.gr
Abstract
BACKGROUND: Treatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity. Epirubicin (E) is a less cardiotoxic anthracycline which has also been combined with paclitaxel in the treatment of MBC. MATERIALS AND METHODS: This paper is a review of studies evaluating the pharmacokinetics, toxicity profile, and efficacy of the ET combination in MBC. RESULTS: The ET combination has been studied extensively in Europe. The unique pharmacokinetics of the combination do not lead to the accumulation of cardiotoxic metabolites as in the case of the doxorubicin-paclitaxel combination. In terms of efficacy, the ET combination yields an overall response rate of 50%-70% and complete response rate (CR) 10%-15% in MBC in the same range as the more recent doxorubicin paclitaxel studies. CONCLUSION: In summary the ET combination is safe and effective in MBC. It is less cardiotoxic than the doxorubicin paclitaxel combination. Further studies with ET in both the adjuvant setting and in MBC are in progress.
BACKGROUND: Treatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity. Epirubicin (E) is a less cardiotoxicanthracycline which has also been combined with paclitaxel in the treatment of MBC. MATERIALS AND METHODS: This paper is a review of studies evaluating the pharmacokinetics, toxicity profile, and efficacy of the ET combination in MBC. RESULTS: The ET combination has been studied extensively in Europe. The unique pharmacokinetics of the combination do not lead to the accumulation of cardiotoxic metabolites as in the case of the doxorubicin-paclitaxel combination. In terms of efficacy, the ET combination yields an overall response rate of 50%-70% and complete response rate (CR) 10%-15% in MBC in the same range as the more recent doxorubicinpaclitaxel studies. CONCLUSION: In summary the ET combination is safe and effective in MBC. It is less cardiotoxic than the doxorubicinpaclitaxel combination. Further studies with ET in both the adjuvant setting and in MBC are in progress.
Authors: Gowhar Shafi; Tarique N Hasan; Naveed Ahmed Syed; Amal A Al-Hazzani; Ali A Alshatwi; A Jyothi; Anjana Munshi Journal: Mol Biol Rep Date: 2012-02-05 Impact factor: 2.316
Authors: Zhuojun Wu; Kevin Chen; Ibrahim Yildiz; Anouk Dirksen; Rainer Fischer; Philip E Dawson; Nicole F Steinmetz Journal: Nanoscale Date: 2012-04-16 Impact factor: 7.790
Authors: K H Yeh; Y S Lu; C H Hsu; J F Lin; H J Chao; T C Huang; C Y Chung; C S Chang; C H Yang; A L Cheng Journal: Br J Cancer Date: 2005-03-28 Impact factor: 7.640
Authors: Ahmed Qasem Ali; Mohammad Abul Farah; Faisal M Abou-Tarboush; Khalid M Al-Anazi; M Ajmal Ali; Joongku Lee; Waleed A Q Hailan; Ahmed Hossam Mahmoud Journal: Saudi J Biol Sci Date: 2018-12-30 Impact factor: 4.219
Authors: Bin Liu; Mei Han; Rong-Hua Sun; Jun-Jie Wang; Yan-Ping Zhang; Di-Qun Zhang; Jin-Kun Wen Journal: Breast Cancer Res Date: 2010-01-25 Impact factor: 6.466